- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03899623
Multi-modal Imaging and Artificial Intelligence Diagnostic System for Multi-level Clinical Application
March 31, 2019 updated by: Jin Yuan, Zhongshan Ophthalmic Center, Sun Yat-sen University
This study is to build an multi-modal artificial intelligence ophthalmological imaging diagnostic system covering multi-level medical institutions.
We are going to evaluate this system in an evidence-based medicine view, taking diabetic retinopathy as an example.
And clinical diagnostic criteria will be made based on this multi-modal artificial intelligence imaging diagnostic system.
The study is designed as a cross-sectional study involving 1,000 normal individuals, 1,000 diabetes patients without ocular complications, and 1,000 with diabetic ocular complications.
Statistical analysis of the diagnostic sensitivity and specificity of the artificial intelligence system will be made, and ROC curve wil be draw.
Study Overview
Status
Unknown
Conditions
Study Type
Observational
Enrollment (Anticipated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Recruiting
- Zhongshan Opthalmic Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Stratified sampling
Description
Inclusion Criteria:
Group A(normal individuals): Meet all the items 1 ~ 5 below
- No familial or hereditary retinopathy;
- No history of ocular trauma and / or history of ocular disease (except for mild to moderate refractive errors and / or age-related cataracts);
- No drug use history that may cause side effects of retina (such as chloroquine, hydroxychloroquine, chlorpromazine, rifampin, etc.); 4 binocular diopter ≤ ± 6.00D; No systemic diseases that may affect the retina.
Group B(diabetes patients without ocular complications): meet any of 1 to 3, and both 4 to 5 items
- Diagnosed with type 1 diabetes for more than 5 years;
- Diagnosed with type 2 diabetes patients;
- Diagnosis of gestational diabetes patients;
- Without systemic disease that may affect the retina except for diabetes;
- Meet the standards of 1 to 4 items.
Group C(patients with diabetic ocular complications): meet with any of 1 to 3, and all 4 to 6 items
- Diagnosed with type 1 diabetes for more than 5 years;
- Diagnosed with type 2 diabetes patients;
- Diagnosis of gestational diabetes patients;
- Meet the guidelines for diagnosis and treatment of diabetic retinopathy in any stage of diabetic retinopathy and / or diabetic macular edema.
- Without systemic disease that may affect the retina except for diabetes;
- A group to meet the criteria for 1 to 4 items.
Exclusion Criteria:
- Refractive pathway is turbid, so that fundus image can not be clearly photographed;
- With other fundus diseases and / or other diseases that seriously affect the visual function;
- Any eye infection, such as conjunctivitis, keratitis, scleritis, endophthalmitis, acute and chronic dacryocystitis, or eye injury;
- Serious systemic diseases such as diabetes, hypertension, heart failur,renal failure;
- Can not cooperate with the examiner due to mental or other reasons.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The diagnostic sensitivity, specificity and ROC curve of the artificial intelligence(AI) system compared with reference standard (ophthalmologist).
Time Frame: It will take 15~20min for each subject to take the exams.
|
Sensitivity: the percentage of diabetic retinopathy(DR) patients who are correctly identified as having the condition by AI.
Sensitivity=True positive/(True positive+False negative).
Specificity: the percentage of healthy people who are correctly identified as not having the condition by AI.
Specificity=True negative /(True negative +False positive).
The ROC curve was plotted with true positive rate (sensitivity) as the ordinate and false positive rate (1-specificity) as the abscissa.
|
It will take 15~20min for each subject to take the exams.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yuan Jin, Professor, Zhongshan Opthalmic Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 23, 2018
Primary Completion (Anticipated)
December 31, 2019
Study Completion (Anticipated)
December 31, 2019
Study Registration Dates
First Submitted
March 29, 2019
First Submitted That Met QC Criteria
March 31, 2019
First Posted (Actual)
April 2, 2019
Study Record Updates
Last Update Posted (Actual)
April 2, 2019
Last Update Submitted That Met QC Criteria
March 31, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017KYPJ104
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States